The effect of Dapagliflozin in the 6-minute walk test of patients with Heart Failure with preserved EF
Heart failure with preserved ejection fraction is a clinical syndrome associated with a significant functional limitation.
No treatment has yet been found to improve exercise performance in these patients.
In a recent randomized study including 289 HFpEF patients, it was demonstrated that patients receiving dapagliflozin after a 12 week-period exhibited an improvement in 6MWT by 15 meters compared to placebo. The beneficial response to dapagliflozin was consistent across all pre-specified subgroups.
Dapagliflozin, and possibly other SGLT-2 agents, should be strongly considered in patients with HFpEF, in order to enhance their functional capacity and quality of life.
Circulation: Heart Failure
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction:
Circ Heart Fail 2023 Oct 23;[EPub Ahead of Print], GD Lewis, K Gosch, LP Cohen, ME Nassif, SL Windsor,
BA Borlaug, DW Kitzman, SJ Shah, T Khumri, G Umpierrez, S Lamba, K Sharma, SS Khan, MN Kosiborod,